Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ALX Oncology stock | $54.88

Learn how to easily invest in ALX Oncology stock.

ALX Oncology Holdings Inc is a biotechnology business based in the US. ALX Oncology shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. ALX Oncology employs 29 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in ALX Oncology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALXO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ALX Oncology stock price (NASDAQ: ALXO)

Use our graph to track the performance of ALXO stocks over time.

ALX Oncology shares at a glance

Information last updated 2021-10-16.
Latest market close$54.88
52-week range$38.09 - $110.00
50-day moving average $72.01
200-day moving average $63.49
Wall St. target price$98.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.62

Buy ALX Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ALX Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ALX Oncology price performance over time

Historical closes compared with the close of $54.88 from 2021-10-20

1 week (2021-10-14) -7.76%
1 month (2021-09-21) -27.79%
3 months (2021-07-21) -6.00%
6 months (2021-04-21) -5.38%
1 year (2020-10-21) 28.55%
2 years (2019-10-17) N/A
3 years (2018-10-17) N/A
5 years (2016-10-17) N/A

ALX Oncology financials

Gross profit TTM $107,000
Return on assets TTM -13.86%
Return on equity TTM -23.97%
Profit margin 0%
Book value $10.04
Market capitalisation $2.4 billion

TTM: trailing 12 months

Shorting ALX Oncology shares

There are currently 2.3 million ALX Oncology shares held short by investors – that's known as ALX Oncology's "short interest". This figure is 6.7% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting ALX Oncology shares can be evaluated.

ALX Oncology's "short interest ratio" (SIR)

ALX Oncology's "short interest ratio" (SIR) is the quantity of ALX Oncology shares currently shorted divided by the average quantity of ALX Oncology shares traded daily (recently around 185000.64516129). ALX Oncology's SIR currently stands at 12.4. In other words for every 100,000 ALX Oncology shares traded daily on the market, roughly 12400 shares are currently held short.

However ALX Oncology's short interest can also be evaluated against the total number of ALX Oncology shares, or, against the total number of tradable ALX Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ALX Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ALX Oncology shares in existence, roughly 60 shares are currently held short) or 0.1323% of the tradable shares (for every 100,000 tradable ALX Oncology shares, roughly 132 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ALX Oncology.

Find out more about how you can short ALX Oncology stock.

ALX Oncology share dividends

We're not expecting ALX Oncology to pay a dividend over the next 12 months.

ALX Oncology overview

ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.

Frequently asked questions

What percentage of ALX Oncology is owned by insiders or institutions?
Currently 14.4% of ALX Oncology shares are held by insiders and 88.15% by institutions.
How many people work for ALX Oncology?
Latest data suggests 29 work at ALX Oncology.
When does the fiscal year end for ALX Oncology?
ALX Oncology's fiscal year ends in December.
Where is ALX Oncology based?
ALX Oncology's address is: 866 Malcolm Road, Burlingame, CA, United States, 94010
What is ALX Oncology's ISIN number?
ALX Oncology's international securities identification number is: US00166B1052

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site